Tag: MONOGRAPH

  • Alpha-Klotho

    Type I transmembrane protein and circulating endocrine factor of the glycosyl hydrolase family 1 superfamily with obligate FGF23 co-receptor and pleiotropic anti-aging functions

    A kidney-derived transmembrane glycoprotein and its shed soluble ectodomain, identified through insertional mutagenesis in 1997 as a suppressor of aging phenotypes in mice, functioning both as an obligate co-receptor for fibroblast growth factor 23 in mineral metabolism and as a circulating endocrine factor that inhibits insulin/IGF-1, Wnt, TGF-beta, and NF-kappaB signaling pathways with demonstrated neuroprotective, cardioprotective, and renoprotective activity in preclinical models.

    Abstract

    Alpha-Klotho (alpha-KL) is a 130 kDa type I single-pass transmembrane protein encoded by the KL gene on human chromosome 13q13.1, first identified in 1997 by Kuro-o et al. through characterization of an insertional mutation in mice that produced a syndrome of accelerated aging encompassing soft tissue calcification, arteriosclerosis, skin atrophy, osteoporosis, emphysema, gonadal dysplasia, and dramatically shortened lifespan [1]. The protein comprises a short intracellular domain, a single transmembrane helix, and a large extracellular region containing two tandem glycosyl hydrolase family 1 (GH1) domains, designated KL1 and KL2, which share sequence homology with family 1 beta-glucosidases but lack catalytic activity against conventional substrates due to substitutions in the active-site residues. The extracellular domain undergoes proteolytic shedding by ADAM10, ADAM17, and BACE1, generating a soluble ectodomain (sKL) comprising KL1 and KL2 that circulates as an endocrine factor detectable in plasma, cerebrospinal fluid, and urine. A shorter secreted isoform containing only KL1 is produced by alternative mRNA splicing.

    In its membrane-bound form, alpha-Klotho functions as an obligate co-receptor for fibroblast growth factor 23 (FGF23), forming a ternary complex with FGF receptor 1c (FGFR1c) that is essential for phosphaturic signaling in the renal proximal tubule and for suppression of 1,25-dihydroxyvitamin D3 (calcitriol) synthesis. The crystal structure of the alpha-Klotho/FGFR1c/FGF23 ternary complex, resolved by Chen et al. (2018) at 3.0 angstrom resolution, demonstrated that the KL2 domain of alpha-Klotho cradles FGF23 with a receptor-binding arm extending from the KL1-KL2 interdomain cleft, creating a composite binding surface for FGF23 engagement [2]. Loss of this co-receptor function produces the hyperphosphatemia, hypervitaminosis D, and ectopic calcification that characterize the kl/kl mouse phenotype and that are recapitulated in FGF23 knockout mice.

    Independent of the FGF23 co-receptor function, soluble alpha-Klotho acts as a circulating endocrine factor with pleiotropic anti-aging activity. Characterized signaling activities include inhibition of the insulin/insulin-like growth factor 1 (IGF-1) pathway through suppression of receptor autophosphorylation; suppression of Wnt/beta-catenin signaling through direct binding to Wnt ligands; inhibition of transforming growth factor beta (TGF-beta) type II receptor signaling and downstream Smad phosphorylation; suppression of NF-kappaB-driven inflammatory transcription; and regulation of ion channel and transporter activity in the renal tubule, including TRPV5, TRPV6, ROMK1, and the Na+/K+-ATPase [3, 4, 5]. These FGF23-independent activities are the molecular basis for the broader anti-aging, neuroprotective, cardioprotective, and anti-fibrotic effects observed in gain-of-function and supplementation studies.

    Circulating soluble alpha-Klotho levels decline with age in humans, beginning approximately in the fourth decade of life, and are markedly reduced in chronic kidney disease, where loss of renal alpha-Klotho expression precedes and contributes to the mineral and bone disorder, cardiovascular calcification, and accelerated aging phenotype of uremia [6]. Epidemiological studies have identified inverse associations between circulating soluble alpha-Klotho concentrations and all-cause mortality, cardiovascular events, and cognitive decline in community-dwelling older adults [7]. The KL-VS haplotype (defined by the F352V and C370S variants, rs9536314 and rs9527025) has been associated in some cohorts with altered klotho secretion, cortical brain volume, and cognitive resilience in aging, though replication across large cohorts remains inconsistent [8, 9].

    Preclinical studies have demonstrated that recombinant alpha-Klotho protein administration, adeno-associated virus-mediated KL gene transfer, and transgenic KL overexpression produce renoprotection in ischemia-reperfusion injury and unilateral ureteral obstruction models; cardioprotection with attenuation of left ventricular hypertrophy and fibrosis; suppression of vascular calcification; and cognitive enhancement in aged, young, and alpha-synuclein transgenic mice through NMDA receptor-dependent glutamatergic mechanisms [10, 11, 12, 13]. A 2023 study in aged nonhuman primates demonstrated that a single subcutaneous injection of a klotho protein fragment enhanced spatial and working memory, representing the first primate cognitive enhancement data for the compound [14].

    As of 2026, alpha-Klotho is in early clinical development. Klothea Bio launched a Phase 1b randomized, double-blind, placebo-controlled trial of AKL003, an alpha-Klotho mRNA therapeutic administered intravenously, in healthy adult volunteers in February 2026. Klotho Neurosciences is advancing KLTO-202, a KL gene therapy, toward first-in-human studies for amyotrophic lateral sclerosis. No alpha-Klotho protein or gene therapy product has received regulatory approval in any jurisdiction. Recombinant human alpha-Klotho protein is available from multiple research suppliers (R&D Systems, Abcam, Sino Biological, Thermo Fisher) for in vitro and preclinical applications. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • GB-115

    Retrodipeptide cholecystokinin-1 (CCK-1) receptor antagonist with anxiolytic, anti-inflammatory, analgesic, and immunomodulatory activity

    A synthetic retrodipeptide analogue of cholecystokinin tetrapeptide (CCK-4) designed at the Zakusov Research Institute of Pharmacology, distinguished by selective central CCK-1 receptor antagonism, non-benzodiazepine anxiolytic activity, and a favorable safety profile confirmed through Phase 3 clinical evaluation under the trade name Ranquilon.

    Abstract

    GB-115 (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide; CAS 678996-63-9) is a synthetic retrodipeptide analogue of the endogenous anxiogenic tetrapeptide cholecystokinin-4 (CCK-4, Trp-Met-Asp-Phe-NH2), designed and synthesized at the V.V. Zakusov Research Institute of Pharmacology (Russian Academy of Medical Sciences) using the topochemical Shemyakin-Ovchinnikov-Ivanov principle for rational peptide drug design. The biologically active conformation of GB-115 has been identified by nuclear Overhauser effect NMR spectroscopy as a type II beta-turn, with the native spatial distance between the phenyl and indolyl hydrophobic pharmacophores critical for receptor interaction. Structure-activity relationship studies demonstrated that L-tryptophan-containing derivatives produce anxiolytic effects, while D-tryptophan-containing enantiomers produce anxiogenic effects mirroring CCK-4 itself, confirming the stereospecificity of the CCK-1 receptor interaction.

    Preclinical pharmacology extends beyond anxiolysis. GB-115 potentiates morphine-induced analgesia through supraspinal opioidergic mechanisms and produces independent antinociceptive activity in chemical and thermal pain models with a significant non-opioid component. Immunomodulatory activity includes stimulation of phagocytic activity of peritoneal macrophages and humoral immune response in intact mice and immunocorrecting effects in animals with secondary immunodeficiency. The compound reverses antinociceptive tolerance to morphine on sub-chronic co-administration, a property consistent with its CCK-1 receptor antagonist mechanism given the established role of cholecystokinin in opioid tolerance.

    Pharmacokinetics are characterized by rapid oral absorption, low absolute bioavailability (approximately 4.65 percent in animal models), and a short elimination half-life of approximately 1.0 hour in humans. The amide bond confers greater peptidase resistance than native peptide bonds, extending plasma detection time relative to unmodified dipeptides.

    Clinical evaluation has progressed through Phase 2 and Phase 3 trials. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Retinalamin

    Polypeptide bioregulator complex derived from bovine retinal tissue with retinoprotective and neurotrophic activity

    A tissue-derived polypeptide fraction developed at the St. Petersburg Institute of Bioregulation and Gerontology as a retinoprotective agent, distinguished from conventional neuroprotective ophthalmologics by its multi-peptide composition, tissue-specific gene expression regulation, and clinical application across glaucoma, diabetic retinopathy, and hereditary retinal dystrophies.

    Abstract

    Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight not exceeding 10,000 daltons, isolated from bovine retinal tissue and developed as a retinoprotective peptide bioregulator by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology of the Russian Academy of Medical Sciences. The compound is registered in the Russian Federation and several Commonwealth of Independent States jurisdictions as a lyophilized preparation for parabulbar and intramuscular injection, manufactured by Geropharm LLC under the ATC code S01XA (other preparations for eye disease treatment). Retinalamin represents a distinct pharmacological class within ophthalmic neuroprotection: rather than a single molecular entity with a defined receptor target, it consists of a heterogeneous mixture of short-chain polypeptides (predominantly 2 to 7 amino acid residues in length) that act through tissue-specific modulation of gene expression, stimulation of intracellular protein synthesis, regulation of lipid peroxidation, and normalization of cellular membrane function in retinal photoreceptors, retinal pigment epithelium, and Mueller glial cells.

    The mechanistic basis of Retinalamin activity has been characterized through in vitro and in vivo models at the St. Petersburg Institute. In Xenopus laevis early gastrula ectoderm assays, Retinalamin demonstrated concentration-dependent induction of neuronal differentiation including brain, retinal, and pigment epithelium lineages, establishing the compound as a morphogenetic peptide regulator with tissue-specific inductive capacity. In cell culture, Retinalamin and the related synthetic tetrapeptide Epithalon stimulated proliferation of retinal and pigmented epithelial cells in a tissue-specific and concentration-dependent manner. The proposed molecular mechanism involves sequential binding of constituent short peptides to promoter regions of genes involved in retinal cell differentiation, survival, and metabolic homeostasis, thereby modulating transcriptional activity and downstream protein expression. Pharmacodynamic effects observed in preclinical and clinical settings include stimulation of photoreceptor and retinal cellular element function, improvement of functional interactions between retinal pigment epithelium and photoreceptor outer segments, enhancement of Mueller cell activity and glutamate inactivation, normalization of vascular permeability, and reduction of oxidative stress through regulation of lipid peroxide metabolism.

    Clinical evidence for Retinalamin spans multiple retinal pathologies. In compensated primary open-angle glaucoma, a 180-patient randomized controlled trial (Egorov et al. 2019) demonstrated that intramuscular Retinalamin produced significant retinoprotective effects, with improvement in mean deviation index from negative 5.52 to negative 4.82 decibels, stabilization of ganglion cell complex thickness (versus progressive thinning in controls), and preservation of pattern electroretinography amplitudes over the study period. A subsequent 147-patient randomized trial (Strakhov et al. 2020) demonstrated that biannual Retinalamin courses over 24 months arrested development of glaucomatous optic neuropathy, with retinal nerve fiber layer thickness remaining stable in treated patients versus declining from 83.5 to 76.7 micrometers in controls. In diabetic retinopathy, a 56-patient comparative study (Malakhova et al. 2024) provided objective structural and functional evidence of positive retinal changes with intramuscular Retinalamin in early-stage disease. In hereditary retinal dystrophies, long-term observational data (Razumovskiy et al.) demonstrated that a first course of Retinalamin improved visual acuity in 58.1 percent and visual fields in 64.5 percent of retinal degeneration patients, with repeated courses over 23 to 25 years preserving residual vision in 55.6 percent of patients and preserving object vision in 11.1 percent. In retinal abiotrophy, residual vision was preserved in 100 percent of treated cases. A 498-patient glaucoma study (Erichev et al. 2020) comparing intramuscular, retrobulbar, and combined administration routes demonstrated comparable efficacy across delivery methods, with total threshold retinal sensitivity increasing by 122 to 274 decibels across glaucoma stages.

    The safety profile of Retinalamin is characterized by low adverse event rates. The principal reported events are local injection site reactions (pain, redness, swelling) and rare hypersensitivity reactions including anaphylactic shock and angioneurotic laryngeal edema. The compound is contraindicated during pregnancy (absence of clinical safety data) and in pediatric populations under 18 years for most indications. Pharmacokinetic characterization in the conventional sense is not feasible owing to the multi-component polypeptide composition, which does not permit standard absorption, distribution, metabolism, and elimination analysis of individual constituents. Retinalamin is not approved by the United States Food and Drug Administration, the European Medicines Agency, or other major Western regulatory authorities. The clinical evidence base is derived predominantly from Russian-language literature published in Vestnik Oftalmologii and related journals. Investigators outside the Russian Federation should approach the compound as a research-grade peptide preparation requiring independent analytical verification and should interpret the clinical literature with attention to the methodological standards and reporting conventions of the source publications.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Aminotadalafil

    Synthetic phosphodiesterase type 5 (PDE5) inhibitor analog; tadalafil N-methyl-to-amino substituted derivative

    A synthetic structural analog of tadalafil in which the piperazinedione N-methyl group is replaced by a primary amine, yielding an unapproved phosphodiesterase type 5 inhibitor principally encountered as an undeclared adulterant in dietary supplements marketed for erectile dysfunction.

    Abstract

    Aminotadalafil, formally (6R,12aR)-2-amino-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione (CAS 385769-84-6), is a synthetic structural analog of tadalafil, the selective cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor marketed as Cialis for the treatment of erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. The single structural modification that distinguishes aminotadalafil from the parent drug is the replacement of the N-methyl substituent on the 2-position of the piperazinedione (diketopiperazine) ring with a primary amino group (NH2), a change that alters hydrogen-bonding capacity, basicity, and physicochemical properties while preserving the core beta-carboline-fused diketopiperazine scaffold responsible for PDE5 active-site recognition. Aminotadalafil retains inhibitory activity at PDE5 and exhibits greater than 100 percent cross-reactivity with anti-tadalafil polyclonal antibodies, confirming close structural and immunochemical homology with the parent compound [1]. The compound has not undergone formal preclinical toxicology, human pharmacokinetic characterization, or clinical efficacy evaluation in any regulatory jurisdiction, and it is not approved for human use by any national medicines authority. Its principal significance in the biomedical literature arises from its repeated identification as an undeclared adulterant in dietary supplements, herbal products, and electronic cigarette liquids marketed for sexual enhancement, where it poses uncharacterized risks to consumers who are unaware of its presence and who may be concurrently taking nitrate-containing medications or other agents that interact with the cGMP-nitric oxide signaling pathway [2, 3, 4, 5].

    The analytical chemistry literature on aminotadalafil is substantial. The compound has been identified and structurally characterized by proton and carbon-13 nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry, Fourier transform infrared spectroscopy, and ultraviolet spectrophotometry in dietary supplement matrices across multiple continents, including reports from Latin America, Asia, Europe, and North America [2, 6, 7]. Validated high-performance liquid chromatography with diode array detection (HPLC-DAD) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods permit simultaneous identification and quantification of aminotadalafil alongside other PDE5 inhibitor analogs (hydroxythiohomosildenafil, thiosildenafil, dimethylsildenafil, thiodimethylsildenafil) in complex supplement matrices [3, 8]. A dimeric interaction product of aminotadalafil has also been isolated from adulterated health food products, suggesting that the compound undergoes degradation or condensation reactions under storage conditions encountered in supplement manufacture [9].

    The pharmacological characterization of aminotadalafil is limited. No peer-reviewed study has reported a direct IC50 determination for aminotadalafil against recombinant human PDE5, and no selectivity panel across the eleven mammalian phosphodiesterase families has been published. The compound’s activity is inferred from its structural homology to tadalafil (IC50 approximately 1.8 to 5.0 nanomolar against PDE5) and from the immunochemical cross-reactivity data. Structure-activity relationship studies of the broader tadalafil analog series indicate that modifications at the 2-position of the diketopiperazine ring modulate PDE5 affinity, and that the (6R,12aR) stereochemistry derived from L-tryptophan is essential for potent inhibition [10, 11]. Aminotadalafil preserves this stereochemistry. No human pharmacokinetic, dose-response, or safety data exist; toxicological risk assessment must therefore rely on extrapolation from tadalafil and on the general pharmacology of the PDE5 inhibitor class. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • GDF11

    Transforming growth factor beta superfamily secreted signaling protein (activin/myostatin subclass)

    A TGF-beta superfamily ligand identified as a candidate circulating rejuvenation factor through heterochronic parabiosis experiments, with reported effects on cardiac hypertrophy, skeletal muscle regeneration, cerebrovascular remodeling, and neurogenesis in aged mice, now subject to significant controversy regarding assay specificity, dose-response boundaries, and translational viability.

    Abstract

    Growth differentiation factor 11 (GDF11), also designated bone morphogenetic protein 11 (BMP-11), is a secreted homodimeric signaling protein of the transforming growth factor beta (TGF-beta) superfamily that signals through activin type II receptors (ActRIIA and ActRIIB) and type I receptors ALK4 and ALK5 to activate the canonical SMAD2/3 transcription factor pathway. GDF11 shares approximately 90 percent amino acid identity in its mature signaling domain with myostatin (GDF8), the well-characterized negative regulator of skeletal muscle mass, and is regulated by the same extracellular inhibitors (follistatin, FSTL3, WFIKKN1/2) and the same tolloid-family metalloproteinase activation mechanism. The protein is synthesized as a 407-amino-acid precursor that undergoes sequential proteolytic processing: signal peptide removal, furin-mediated cleavage of the prodomain, and tolloid-dependent liberation of the active mature homodimer from the latent prodomain complex.

    GDF11 became one of the most intensely debated molecules in modern aging biology following landmark publications from the laboratory of Amy Wagers and Richard Lee at Harvard between 2013 and 2014. Using heterochronic parabiosis and systemic delivery of recombinant GDF11, these investigators reported that GDF11 levels decline with age in mice and that restoration of youthful GDF11 concentrations reverses age-related cardiac hypertrophy (Loffredo et al., 2013), restores skeletal muscle stem cell function and enhances muscle repair (Sinha et al., 2014), and induces cerebrovascular remodeling with increased neurogenesis and improved olfactory discrimination in aged animals (Katsimpardi et al., 2014). These findings generated exceptional scientific and public interest, with GDF11 described in the popular press as a circulating “youth factor” or “rejuvenation protein.”

    The initial claims became intensely controversial when independent laboratories demonstrated that the original immunoassays could not reliably distinguish GDF11 from its close homolog myostatin (Egerman et al., 2015; Smith et al., 2015), that circulating GDF11/myostatin immunoreactivity may increase rather than decrease with age when measured by more specific methods, and that supraphysiological recombinant GDF11 administration inhibits rather than promotes skeletal muscle regeneration and can induce severe cachexia, muscle wasting, and premature death in mice (Egerman et al., 2015; Harper et al., 2016; Hammers et al., 2017; Jones et al., 2018). These contradictory findings have not been fully resolved. The current scientific consensus recognizes GDF11 as a biologically important developmental signaling molecule with plausible but unproven therapeutic potential in aging, and regards the magnitude and direction of its age-related changes and the safety window for exogenous administration as open questions requiring further investigation with rigorously validated, myostatin-discriminating assays.

    GDF11 is not approved as a therapeutic agent by any regulatory authority. Sotatercept, an ActRIIA-Fc fusion protein that sequesters GDF11 along with activin A and myostatin, was approved by the United States Food and Drug Administration in March 2024 for pulmonary arterial hypertension, representing the first clinical validation of pharmacological modulation of GDF11-class signaling. No recombinant GDF11 product has entered human clinical trials. The compound is available as a research-grade recombinant protein from multiple commercial suppliers for in vitro and preclinical investigation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Seltorexant

    Selective orexin-2 receptor antagonist (2-SORA) with antidepressant and sleep-promoting activity

    A selective orexin-2 receptor antagonist developed by Janssen Pharmaceuticals and Minerva Neurosciences as an adjunctive treatment for major depressive disorder with insomnia symptoms, distinguished from dual orexin receptor antagonists by its high OX2R selectivity, rapid pharmacokinetic profile, and demonstrated antidepressant efficacy through modulation of orexinergic hyperarousal.

    Abstract

    Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA to advance through Phase 3 clinical trials for major depressive disorder (MDD) with insomnia symptoms. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R and negligible affinity for other receptors, transporters, or ion channels in a panel of 50 assays, a selectivity profile that distinguishes it mechanistically from the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant approved for primary insomnia. Pharmacokinetics are characterized by rapid oral absorption (median time to maximum plasma concentration 0.3 to 1.5 hours), a short elimination half-life of approximately 2 to 3 hours, and metabolism predominantly through cytochrome P450 3A4, producing a pharmacokinetic profile suited to bedtime administration with minimal next-day residual effects. Preclinical pharmacology in rodent models demonstrated dose-dependent increases in non-rapid eye movement (NREM) sleep duration, reduced sleep onset latency, attenuation of stress-induced adrenocorticotropic hormone (ACTH) release, suppression of hypothalamic-pituitary-adrenal (HPA) axis activation, and absence of effects on dopaminergic reward pathways or motor coordination. The specificity of these effects for OX2R was confirmed by the absence of activity in OX2R knockout mice. Brain penetration and receptor occupancy were confirmed by positron emission tomography imaging in rats and by in vivo competitive radioligand binding studies. The clinical evidence base spans Phase 1 through Phase 3 development. The pivotal Phase 3 MDD3001 trial achieved its primary and all secondary endpoints, with seltorexant 20 mg adjunctive to SSRI or SNRI producing a statistically significant least-squares mean difference from placebo of negative 2.6 points on MADRS total score at day 43 (p = 0.007) and significant improvement in PROMIS Sleep Disturbance (negative 3.7, p < 0.001). The Phase 3 MDD3005 active-comparator study against quetiapine extended-release demonstrated a numerically higher response rate for seltorexant (57.4 percent versus 53.4 percent) that did not reach statistical significance, but with substantially fewer adverse events, lower somnolence incidence (6 percent versus 24 percent), and markedly less weight gain (0.5 kg versus 2.1 kg over 26 weeks). A separate monotherapy Phase 1b study (2024) in 128 MDD patients demonstrated antidepressant activity independent of adjunctive SSRI or SNRI use. The compound is well tolerated across the clinical program. The most common treatment-emergent adverse events are headache, somnolence, and nausea at incidences comparable to placebo. No deaths, serious treatment-emergent adverse events, clinically significant cardiovascular changes, or suicidal behavior events have been reported in the seltorexant treatment arms. No cataplexy has been observed. The compound does not produce conditioned place preference in mice, does not increase extracellular dopamine release in rat nucleus accumbens, and does not impair motor coordination at sleep-promoting doses, supporting a favorable abuse liability and safety profile relative to benzodiazepines and Z-drugs. Seltorexant has not yet received regulatory approval in any jurisdiction. Phase 3 clinical trials for adjunctive MDD with insomnia symptoms are ongoing, and Phase 2 investigation for primary insomnia and Alzheimer's disease is in progress. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Apelin-13

    Endogenous bioactive peptide agonist of the apelin receptor (APJ/APLNR), a class A G protein-coupled receptor

    A pyroglutamyl-modified tridecapeptide derived from the C-terminus of preproapelin, identified as the predominant circulating isoform and the highest-potency endogenous agonist of the APJ receptor, with characterized cardiovascular inotropic, vasodilatory, aquaretic, metabolic, and neuroprotective activities.

    Abstract

    Apelin-13, the C-terminal tridecapeptide fragment of the 77-amino-acid preproapelin precursor, is the most potent endogenous agonist of the apelin receptor (APJ, also designated APLNR), a class A rhodopsin-like G protein-coupled receptor originally cloned as an orphan receptor in 1993 by O’Dowd et al. on the basis of sequence homology with the angiotensin II type 1 receptor. The receptor was deorphanized in 1998 by Tatemoto and colleagues at the Takeda Chemical Research Institute, who isolated apelin from bovine stomach extracts using an extracellular acidification assay on APJ-expressing Chinese hamster ovary cells and demonstrated that apelin-13 displayed 8- to 60-fold higher potency than the longer apelin-36 isoform. The predominant circulating form in human plasma is [Pyr1]apelin-13 (pyroglutamyl apelin-13), in which the N-terminal glutamine residue undergoes spontaneous or enzymatic cyclization to pyroglutamate, conferring modest resistance to aminopeptidase degradation and representing the principal bioactive isoform in cardiovascular tissue and plasma.

    Apelin-13 activates APJ with sub-nanomolar potency (EC50 approximately 0.37 nM in cellular acidification assays), coupling predominantly through Gi/o proteins to inhibit adenylyl cyclase and reduce intracellular cAMP, through Gq/11 to activate phospholipase C and mobilize intracellular calcium, and through G12/13 to engage RhoA-dependent cytoskeletal rearrangement. The receptor also recruits beta-arrestin 1 and 2, mediating receptor internalization and activating extracellular signal-regulated kinase 1/2 (ERK1/2) through G protein-independent pathways. The downstream signaling cascade includes activation of phosphoinositide 3-kinase (PI3K)/Akt, endothelial nitric oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and inhibition of reactive oxygen species generation, collectively producing the cardiovascular, metabolic, and cytoprotective effects that define the pharmacological profile.

    The cardiovascular pharmacology of apelin-13 is the most extensively characterized domain. In human clinical studies, systemic infusion of [Pyr1]apelin-13 at 30 to 300 nmol/min produces a sustained approximately 10 percent increase in cardiac index, increased ejection fraction, reduced systemic vascular resistance by approximately 12 percent, and reduced mean arterial pressure by approximately 4 percent, effects observed in both healthy volunteers and patients with chronic heart failure and chronic kidney disease. The mechanism involves direct positive inotropic action on cardiomyocytes through APJ-mediated calcium sensitization, nitric oxide-dependent vasodilation in resistance arteries, and counter-regulatory opposition to the renin-angiotensin-aldosterone system. Preclinical models demonstrate cardioprotective effects in myocardial infarction, ischemia-reperfusion injury, pressure-overload hypertrophy, and diabetic cardiomyopathy, with mechanisms including salvage of the peri-infarct border zone, mobilization of endogenous cardiac stem cells, and suppression of pathological fibrosis.

    The renal pharmacology is defined by the functional antagonism between apelin and arginine vasopressin (AVP) at the collecting duct. Apelin-13 inhibits vasopressin-induced translocation of aquaporin 2 (AQP2) water channels to the apical membrane of principal cells through Gi-mediated inhibition of cAMP/protein kinase A signaling, producing a diuretic (aquaretic) effect that opposes AVP-driven water reabsorption. This reciprocal regulation positions the apelin/AVP axis as a physiological rheostat for water homeostasis, with therapeutic implications for hyponatremia and states of AVP excess.

    Metabolic pharmacology encompasses insulin-sensitizing and glucoregulatory effects. Apelin-13 administration in diabetic rodent models reduces blood glucose, increases serum insulin, improves pancreatic islet mass, and enhances glucose uptake in skeletal muscle through AMPK-dependent GLUT4 translocation. Neuroprotective activity has been demonstrated in models of ischemic stroke, diabetes-associated cognitive decline, and excitotoxic injury, with mechanisms including antioxidant defense through the SIRT3/FoxO3 pathway, anti-inflammatory cytokine modulation, and direct neuronal survival signaling through PI3K/Akt.

    The principal pharmacokinetic limitation of apelin-13 is its extremely short plasma half-life. Native [Pyr1]apelin-13 has a plasma half-life of approximately 21 to 24 minutes in rodents, driven by rapid proteolytic degradation at the Leu5-Ser6 peptide bond by neprilysin, angiotensin-converting enzyme 2 (ACE2), and plasma kallikrein. This has motivated extensive medicinal chemistry efforts to develop stabilized analogues (macrocyclic peptides, D-amino acid substitutions, PEGylation) and small-molecule APJ agonists (AMG-986, BMS-986224, azelaprag) for chronic administration.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Glutathione

    Endogenous tripeptide thiol antioxidant and phase II conjugation cofactor

    The principal low-molecular-weight thiol in mammalian cells, serving as the dominant intracellular antioxidant, electrophile conjugation substrate, and redox signaling mediator across virtually all aerobic tissues.

    Abstract

    Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine; GSH) is a ubiquitous tripeptide thiol present in virtually all mammalian cells at intracellular concentrations of 1 to 10 millimolar, constituting the single most abundant non-protein sulfhydryl compound in animal tissues and the central node of cellular redox homeostasis. First isolated by Sir Frederick Gowland Hopkins in 1921 from yeast, blood, and muscle tissue and subsequently characterized as a gamma-linked glutamyl-cysteinyl-glycine tripeptide by Hopkins and colleagues over the following decade, glutathione occupies a singular position in biochemistry: it is simultaneously the principal intracellular reductant maintaining the thiol-disulfide balance of cytosolic and mitochondrial protein pools; the obligate cofactor for glutathione peroxidases (GPx1 through GPx8), glutathione S-transferases (GST alpha, mu, pi, theta, sigma, kappa, omega, and zeta classes), and glutaredoxins; and the substrate for phase II xenobiotic conjugation reactions that render electrophilic metabolites water-soluble for biliary and renal excretion. The reduced form (GSH) predominates under physiological conditions, typically exceeding the oxidized disulfide form (GSSG) by a ratio of 100:1 in the cytosol, with the GSH/GSSG redox couple establishing the electrochemical set point against which cellular redox-sensitive signaling cascades operate, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, NF-kappaB modulation, and apoptosis signal-regulating kinase 1 (ASK1) regulation.

    Biosynthesis proceeds through two sequential ATP-dependent enzymatic steps: gamma-glutamylcysteine ligase (GCL, formerly gamma-glutamylcysteine synthetase) catalyzes the rate-limiting condensation of L-glutamate and L-cysteine via an atypical gamma-carboxyl peptide bond, and glutathione synthetase (GSS) subsequently ligates glycine to the gamma-glutamylcysteine dipeptide. Both enzymes are transcriptionally regulated by the Nrf2-Keap1-ARE (antioxidant response element) pathway, establishing a feedback loop in which oxidative or electrophilic stress induces Nrf2 nuclear translocation, upregulates GCL and GSS expression, and thereby increases glutathione synthesis capacity. Cysteine availability is typically the rate-limiting substrate for biosynthesis, a constraint that underwrites the therapeutic rationale for N-acetylcysteine (NAC) as an indirect glutathione precursor strategy.

    The pharmacokinetics of exogenous glutathione are dominated by poor oral bioavailability. The intact tripeptide is a substrate for gamma-glutamyltransferase (GGT) at the intestinal brush border and for intraluminal peptidases, resulting in extensive presystemic hydrolysis. Early pharmacokinetic studies in humans reported negligible increases in plasma or erythrocyte glutathione after single oral doses of reduced glutathione. These findings, together with subsequent work on liposomal, sublingual, and S-acetyl glutathione delivery systems that partially circumvent presystemic hydrolysis, have rekindled interest in direct glutathione supplementation as a complement to the established precursor strategy.

    Clinically, glutathione depletion has been documented in a broad spectrum of disease states characterized by chronic oxidative stress, including Parkinson disease (40 percent depletion in the substantia nigra at preclinical stages), nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, HIV/AIDS, cystic fibrosis, and age-related decline. Interventional evidence remains modest relative to the scope of the preclinical and epidemiological literature. In hepatic applications, intravenous glutathione is used clinically in several jurisdictions as adjunctive therapy for drug-induced liver injury and for the potentiation of NAC in acetaminophen toxicity, where the glutathione-NAPQI conjugation pathway is the principal detoxification mechanism.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sildenafil

    Selective phosphodiesterase type 5 (PDE5) inhibitor of the pyrazolopyrimidinone structural class

    A pyrazolopyrimidinone-based cyclic GMP-specific phosphodiesterase type 5 inhibitor originally developed at Pfizer as an antianginal agent, repositioned as the first oral pharmacotherapy for erectile dysfunction and subsequently approved for pulmonary arterial hypertension, with an expanding preclinical evidence base in cardioprotection, neuroprotection, and vascular inflammation.

    Abstract

    Sildenafil (UK-92480) is a potent, competitive, and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the enzyme principally responsible for hydrolytic degradation of cGMP in vascular smooth muscle, the corpus cavernosum, and the pulmonary vasculature. The compound was synthesized at the Pfizer Global Research and Development laboratories in Sandwich, Kent, United Kingdom in 1989 as part of a medicinal chemistry program targeting selective PDE5 inhibition for the treatment of angina pectoris and hypertension. Phase I clinical trials revealed limited antianginal efficacy but a pronounced and reproducible effect on penile erection, prompting repositioning toward erectile dysfunction. Sildenafil received United States Food and Drug Administration (FDA) approval on 27 March 1998 as the first oral pharmacotherapy for erectile dysfunction (marketed as Viagra) and subsequently received FDA approval in June 2005 for the treatment of World Health Organization Group I pulmonary arterial hypertension (marketed as Revatio).

    The pharmacological mechanism is inhibition of PDE5 at the catalytic site with an IC50 of approximately 3.5 nanomolar and selectivity over PDE1 through PDE4 of 80- to 19,000-fold, with approximately 10-fold selectivity over the structurally related retinal PDE6, the latter accounting for the dose-dependent visual disturbances observed clinically [1, 2]. PDE5 inhibition potentiates the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP signaling cascade: in tissues where NO release occurs (penile corpus cavernosum during sexual stimulation, pulmonary vascular endothelium), sildenafil amplifies the downstream smooth muscle relaxation by preventing cGMP breakdown. The compound does not directly initiate smooth muscle relaxation in the absence of NO signaling, a pharmacological distinction that differentiates PDE5 inhibitors from direct NO donors and from soluble guanylyl cyclase stimulators.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak plasma concentration approximately 60 minutes under fasting conditions), moderate absolute oral bioavailability of approximately 41 percent (limited by hepatic first-pass metabolism), a plasma elimination half-life of approximately 3 to 5 hours, and high plasma protein binding of approximately 96 percent [3, 4]. Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4, major pathway) and CYP2C9 (minor pathway), producing the active N-desmethyl metabolite (UK-103,320) that retains approximately 50 percent of the parent compound potency at PDE5 and has a similar terminal half-life [3]. The CYP3A4 dependence creates clinically significant drug-drug interactions with strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin), which can elevate sildenafil plasma concentrations by 3- to 11-fold.

    The clinical evidence base spans two FDA-approved indications (erectile dysfunction and pulmonary arterial hypertension) and multiple investigational applications including Raynaud phenomenon, heart failure, altitude sickness, and neuroprotection. Preclinical pharmacology has established cardioprotective effects against ischemia-reperfusion injury through mitochondrial ATP-sensitive potassium channel opening, neuroprotective effects in rodent stroke and neurodegeneration models through cGMP-mediated anti-apoptotic signaling, and anti-inflammatory effects through suppression of NF-kappaB-driven cytokine release.

    The compound is well tolerated at approved doses. Principal adverse events are headache (16 percent), flushing (10 percent), dyspepsia (7 percent), nasal congestion (4 percent), and dose-dependent visual disturbances (chromatopsia, increased light sensitivity) reflecting PDE6 cross-inhibition in retinal photoreceptors [7]. The critical safety concern is the absolute contraindication with organic nitrates and nitric oxide donors, where co-administration produces synergistic and potentially fatal hypotension through additive cGMP-mediated vasodilation [8]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Arimistane

    Steroidal mechanism-based (suicide) aromatase inhibitor derived from the 7-oxo-dehydroepiandrosterone metabolic pathway

    A naturally occurring androstadienedione metabolite of 7-keto-DHEA that functions as an irreversible steroidal aromatase inactivator, distinguished from pharmaceutical aromatase inhibitors by its endogenous biosynthetic origin and concurrent reported activity on cortisol regulation through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1.

    Abstract

    Androsta-3,5-diene-7,17-dione, marketed and commonly known as Arimistane, is a steroidal mechanism-based irreversible inhibitor of aromatase (cytochrome P450 19A1, CYP19A1) that occupies a distinctive position in the landscape of estrogen-modulating compounds. Structurally, it is an androstadienedione bearing conjugated 3,5-diene unsaturation in the A/B ring system and a 7-oxo group on the B ring, with the characteristic 17-ketone of the androstane series. The compound is a downstream metabolite of 7-keto-dehydroepiandrosterone (7-keto-DHEA, 3-beta-hydroxyandrost-5-ene-7,17-dione), itself produced from dehydroepiandrosterone (DHEA) by hepatic cytochrome P450 7B1 (CYP7B1) or CYP3A-mediated 7-alpha-hydroxylation followed by 11-beta-hydroxysteroid dehydrogenase (11-beta-HSD) oxidation at the 7-position and subsequent dehydration. This endogenous biosynthetic origin distinguishes Arimistane from fully synthetic aromatase inhibitors such as exemestane, letrozole, and anastrozole.

    The aromatase-inhibitory mechanism of Arimistane belongs to the type I (steroidal, mechanism-based) class characterized by Covey and colleagues in the early 1980s for the structurally related androst-5-ene-7,17-dione series [1, 2]. Mechanism-based inhibition proceeds through initial competitive binding of the steroidal inhibitor to the substrate-binding pocket of aromatase, followed by enzyme-catalyzed oxidative processing that generates a reactive intermediate capable of forming a covalent bond with amino acid residues at or near the active site. The covalent modification permanently inactivates the enzyme molecule; restoration of aromatase activity requires de novo protein synthesis rather than simple inhibitor dissociation. This irreversible (“suicide”) mechanism produces sustained estrogen suppression that persists beyond the plasma residence time of the parent compound, a pharmacodynamic feature shared with the clinically approved steroidal aromatase inactivator exemestane.

    Beyond aromatase inhibition, Arimistane has been reported to modulate cortisol metabolism through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1), the microsomal enzyme that catalyzes the reduction of cortisone to the biologically active glucocorticoid cortisol in liver, adipose tissue, and central nervous system. This activity, attributed to the 7-oxo-androstane structural motif shared with 7-keto-DHEA and its metabolites, is proposed to reduce local cortisol regeneration without affecting adrenal cortisol synthesis directly.

    The regulatory status of Arimistane is restrictive. The United States Food and Drug Administration (FDA) has determined that androsta-3,5-diene-7,17-dione does not meet the statutory definition of a dietary ingredient under section 201(ff)(1) of the Federal Food, Drug, and Cosmetic Act, and has issued multiple warning letters to supplement manufacturers marketing products containing the compound [3]. The World Anti-Doping Agency (WADA) added Arimistane to the Prohibited List in 2017 under the category of hormone and metabolic modulators (class S4), specifically as an aromatase inhibitor [4]. The compound is not approved as a pharmaceutical in any jurisdiction.

    The clinical evidence base for Arimistane is sparse relative to pharmaceutical aromatase inhibitors. No registration-quality clinical trials have been conducted. Published human data are limited to manufacturer-sponsored tolerability assessments and analytical chemistry studies characterizing the compound as a urinary metabolite of 7-keto-DHEA in anti-doping contexts [5]. The pharmacological characterization rests principally on in vitro aromatase inhibition assays, structure-activity relationship inference from the broader androstene-7,17-dione series studied by Covey, Brodie, and colleagues in the 1980s and 1990s [1, 2, 6], and extrapolation from the more extensive clinical pharmacology of the structurally related steroidal aromatase inactivator exemestane. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.